Table 9.
Weighted arithmetic mean, minimum and maximum proportion of resistance (%R or %R + I) and weighted standard deviation (SD) in Streptococcus uberis for the target antimicrobials in each continent. NA means that SD could not be calculated as only one study was included
| Antibiotic | Continent | No. of papers | No. of isolatesa | Weighted arithmetic mean proportion of resistance (%) | Minimum resistance % observed | Maximum resistance % observed | Standard deviation |
|---|---|---|---|---|---|---|---|
| 3GC (Cefoperazone) | Europe | 3 | 1,317 | 5.7 | 0 | 6 | 1 |
| 3GC (Ceftiofur) | Europe | 1 | 56 | 13 | 13 | 13 | NA |
| 3GC (Ceftiofur) | North America | 2 | 1,267 | 3.4 | 3.2 | 6.2 | 0.8 |
| Erythromycin | Asia | 1 | 12 | 0 | 0 | 0 | NA |
| Erythromycin | Europe | 7 | 1,974 | 15.6 | 5.7 | 25 | 3.3 |
| Erythromycin | Oceania | 1 | 703 | 8.9 | 8.9 | 8.9 | NA |
| Fluoroquinolones | Europe | 4 | 1,449 | 27.4 | 0 | 37 | 16.1 |
| Penicillin | Europe | 8 | 1,847 | 6.7 | 0 | 44 | 7.4 |
| Penicillin | Oceania | 2 | 817 | 8.2 | 1 | 9.2 | 2.7 |
| Penicillin‐novobiocin | North America | 1 | 1,171 | 0.3 | 0.3 | 0.3 | NA |
| Pirlimycin | Europe | 3 | 286 | 17.6 | 11.8 | 26 | 6.4 |
| Pirlimycin | North America | 1 | 1,171 | 17.9 | 17.9 | 17.9 | NA |
| Spiramycin | Europe | 4 | 2,716 | 26 | 7.7 | 36.2 | 9.4 |
| Sulfa/TMP | Europe | 5 | 1,803 | 15.2 | 0 | 22 | 9.4 |
| Sulfa/TMP | North America | 1 | 1,171 | 4.9 | 4.9 | 4.9 | NA |
| Sulfa/TMP | Oceania | 1 | 102 | 12.7 | 12.7 | 12.7 | NA |
| Tylosin | Europe | 2 | 831 | 19.5 | 2.9 | 21 | 5 |
a
All isolates were of dairy origin.